AHA Guidelines for ICD Indications

AHA / ACC / HRS Guideline–Based Indications for Implantable Cardioverter Defibrillator (ICD)

(Adapted from American Heart Association / American College of Cardiology / Heart Rhythm Society ventricular arrhythmia and sudden cardiac death guidelines)

---

1. Secondary Prevention (Class I Indications)

ICD is recommended in patients who have already experienced life-threatening ventricular arrhythmias not due to reversible causes.

Indications

• Survivors of cardiac arrest due to VF or hemodynamically unstable VT

• Sustained VT with syncope or hemodynamic instability

• Sustained VT with structural heart disease

• Spontaneous sustained VT even if hemodynamically stable

Important condition

• No reversible cause (e.g., acute ischemia, electrolyte imbalance, drug toxicity)

---

2. Primary Prevention (Class I Indications)

ICD recommended to prevent sudden cardiac death in high-risk patients.

Ischemic Cardiomyopathy

• LVEF ≤35%, NYHA II–III, at least 40 days after MI, on optimal medical therapy, survival expected >1 year

• LVEF ≤30%, NYHA I, ≥40 days after MI

---

Non-Ischemic Dilated Cardiomyopathy

• LVEF ≤35%, NYHA II–III, on guideline-directed medical therapy

---

Post-MI With Ventricular Arrhythmias

• Prior MI + LVEF ≤40% + inducible VT/VF on EPS

---

3. Class IIa Indications (Reasonable)

ICD can be considered in:

• Hypertrophic cardiomyopathy with high-risk features

• Arrhythmogenic right ventricular cardiomyopathy (ARVC)

• Cardiac sarcoidosis with LV dysfunction or VT

• Unexplained syncope with inducible VT

• Long QT syndrome with syncope or VT despite beta-blocker therapy

---

4. Class IIb Indications (May Be Considered)

• Non-ischemic cardiomyopathy with LVEF ≤35% but NYHA I

• Certain genetic channelopathies at intermediate risk

---

5. Class III (Not Indicated / Harm)

ICD not recommended when:

• Life expectancy <1 year

• Reversible causes of VT/VF present

• VT/VF within 48 hours of acute MI

• NYHA class IV HF not candidate for CRT/VAD/transplant

---

Important Waiting Periods

• ≥40 days after MI

• ≥3 months after revascularization or GDMT optimization

---

Key Trials Supporting ICD Therapy

• MADIT II trial

• SCD-HeFT trial

• AVID trial

These trials demonstrated significant reduction in sudden cardiac death with ICD therapy.

---

Practical Clinical Summary

Secondary prevention → ICD almost always indicated

Primary prevention → based mainly on:

• LVEF ≤35%

• NYHA II–III

• Optimal medical therapy

• Expected survival >1 year